Larimar Therapeutics, Inc. Common Stock (LRMR) Stock Price

LRMRStock
$4.16+3.58%52W
Market Cap$432.15M
P/E
PEG Ratio
Div yield
Beta0.69

LRMR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)26.04%
Price vs S&P 500 (4W)2.69%
VGM Score60.13

LRMR Earnings Surprise History

Q2 25-0.41est. -0.49
Q3 25-0.61est. -0.42
Q4 25-0.73est. -0.55
Q1 26-0.31est. -0.59
Q2 26-0.30est. -0.38

LRMR Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.47
4.44
4.44
4.41

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
LRMRLarimar Therapeutics, Inc. Common Stock
B$4.16
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Larimar Therapeutics, Inc. Common Stock

Larimar Therapeutics is a clinical-stage biotechnology company developing treatments for rare genetic diseases using its proprietary cell-penetrating peptide technology platform. Its lead candidate, CTI-1601, is designed to deliver a critical missing protein directly to the mitochondria of patients with Friedreich's ataxia via subcutaneous injection. The company is advancing a novel treatment approach to address a significant unmet medical need in the rare disease space.